GLP-1 Agonists in Psoriasis & HS: What Clinicians Need to Know
GLP-1 receptor agonists are gaining attention beyond diabetes and obesity for their potential role in treating inflammatory skin and joint diseases like psoriasis, psoriatic arthritis, and hidradenitis suppurativa (HS).
Jonathan Aun, DO, FACC, FACP, is the director of noninvasive cardiovascular imaging at Brooke Army Medical Center in San Antonio, TX.
JAA: The views expressed in this editorial are those of Dr Aun and do not reflect the official policy of the United States Air Force, the Department of War, the Defense Health Agency, or the United States Government. The identification of specific products or scientific instrumentation is considered an integral part of the scientific endeavor and does not constitute endorsement or implied endorsement on the part of Dr Aun, the Department of War, or any component agency.
© 2025 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of the The Derm APP or HMP Global, their employees, and affiliates.
Related Content
Where Dermatology NPs and PAs Learn, Lead, and Level Up.
The Derm NP/PA is dedicated to educating and informing advanced practice providers on clinical topics and practical issues to support the profession and improve the quality of patient care across the spectrum of dermatology.
The Derm NP/PA is designed for advanced practice providers who specialize in dermatology to further their education and increase their knowledge to achieve better patient outcomes. Explore cutting-edge research, innovative treatment options, and new therapeutic methods while remaining focused on the fundamental principles and terminology associated with dermatology. Engage year-round with The Derm NP/PA to access clinical insights, interactive features, research news updates, accredited continuing-education programs, and more.
